CD274 and nasopharyngeal carcinoma: The efficacy of anti-PD-1 monoclonal antibody in R/M-NPC may vary depending on the PD-L1 expression status, which raises an important question for investigation as PD-L1 expression could potentially serve as a biomarker for treatment guidance.